GBIM:OTCMKTS
GlobeImmune Inc
US$ 0,00010
0,00%
(0,00) 1D
29 sep, 15:48:52 GMT-4 · USD
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor GBIM genereren…
Beursw.
580,00
Gem. vol.
1,74K
Volume
0,00
52 wk hoog
US$ 0,04
52 wk laag
US$ 0,00
Uitstaande aandelen
5,75 mln.
Aantal medewerkers
22
Beursw.
580,00
Gem. vol.
1,74K
Volume
0,00
52 wk hoog
US$ 0,04
52 wk laag
US$ 0,00
Uitstaande aandelen
5,75 mln.
Aantal medewerkers
22
Nieuwsartikelen
Van webbronnen en nieuwspartners
MarketScreener Nederland
·
14 uur geleden
S&P 500 sluit hoger nu handelaren de overstap maken van AI naar gezondheidszorg
Vietnam.vn
·
9 uur geleden
Kort nieuws 16-10: Dow Jones stijgt met meer dan 550 punten door dalende obligatierentes, PV Power schat de winst over 9 maanden op meer dan 5.400 miljard VND
MarketScreener Nederland
·
22 uur geleden
VS: index van de New York Fed overtreft de verwachtingen ruimschoots
Profiel
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
Over GlobeImmune Inc
CEO-
Medewerkers22
Opgericht1 jan 1995
HoofdkantoorLouisville, Colorado, Verenigde Staten
Sector-
Websiteglobeimmune.com